U
CPXX

UBS’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

UBS’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2K Buy
+860
New +$2.35K ﹤0.01% 10082
2014
Q2 		– Sell
-3,045
Closed -$10K – 11152
2014
Q1 		$10K Buy
3,045
+2,885
+1,803% +$9.76K ﹤0.01% 8943
2013
Q4 		$1K Buy
+160
New +$548 ﹤0.01% 10259

Other funds holding CPXX

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MA
MUFG Americas New York $4.04B AUM 12.45% 1-Year Est. Return

UBS's CPXX Position: Q3 2014 in Review

UBS opened a new position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q3 2014: 860 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #10082 among its holdings. This is a return to the name: UBS previously reported a position in CPXX as recently as Q1 2014.

UBS first reported a position in CPXX in Q4 2013 and has held it in 3 quarters since. The position peaked at $10K in Q1 2014. 13 funds tracked by Wall St. Rank hold CPXX as of Q3 2014.

  • UBS held 860 shares of CELATOR PHARMACEUTICALS INC. COMMON STOCK worth $2K as of Q3 2014.
  • CELATOR PHARMACEUTICALS INC. COMMON STOCK was a new UBS position in Q3 2014.
  • CELATOR PHARMACEUTICALS INC. COMMON STOCK made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10082 holding.
  • UBS first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q4 2013 and has held it in 3 quarters since.
  • UBS's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $10K in Q1 2014.
  • 13 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.